CORD-19:e847d433e7424152a9846673209cb73027415ecd / 99647-99930 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T996","span":{"begin":0,"end":283},"obj":"Sentence"},{"id":"T45933","span":{"begin":0,"end":283},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tigecycline MIC90 of £0.5 lg/ml for grampositive pathogens (including resistant phenotypes) and MIC90 of £2 lg/ml of gram-negative pathogens (excluding P. aeruginosa) validate the potent activity of TIG against community/hospital pathogens isolated in six Asia/Pacific Rim countries."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T41","span":{"begin":0,"end":283},"obj":"Sentence"}],"text":"Tigecycline MIC90 of £0.5 lg/ml for grampositive pathogens (including resistant phenotypes) and MIC90 of £2 lg/ml of gram-negative pathogens (excluding P. aeruginosa) validate the potent activity of TIG against community/hospital pathogens isolated in six Asia/Pacific Rim countries."}